Literature DB >> 6748875

Value of serum immunoglobulins in the diagnosis of liver disease.

D M Martin, D H Vroon, S M Nasrallah.   

Abstract

Serum immunoglobulins were determined in 145 consecutive patients with biopsy-proven steatosis, alcoholic hepatitis, alcoholic hepatitis with fibrosis, alcoholic hepatitis with cirrhosis, inactive cirrhosis, chronic active alcoholic hepatitis, chronic active hepatitis, primary biliary cirrhosis and nonspecific hepatitis. IgM was both a sensitive (90.5%) and specific (86.2%) marker for primary biliary cirrhosis, and mean IgM levels were higher in primary biliary cirrhosis than in other diagnostic categories (p less than 0.05). IgA levels were most commonly elevated in alcoholic liver disease (p less than 0.005). IgA detected 95% of alcoholic disease, but was poorly specific (41.1%). A trend of rising IgA with increasing severity of alcoholic injury was observed, but the differences were not significant. IgG was most commonly elevated in chronic active hepatitis and alcoholic hepatitis with cirrhosis, but the IgG values did not differ significantly from those found in other diagnostic categories. Our results substantiate assertions of a diagnostic sensitivity for elevated IgA in alcoholic liver disease and IgM in primary biliary cirrhosis. With the exception of IgM in primary biliary cirrhosis, however, serum immunoglobulins are not specific markers of liver histology.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6748875     DOI: 10.1111/j.1600-0676.1984.tb00930.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

1.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities.

Authors:  A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

2.  Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis.

Authors:  Anand S Mehta; Ronald E Long; Mary Ann Comunale; Mengjun Wang; Lucy Rodemich; Jonathan Krakover; Ramila Philip; Jorge A Marrero; Raymond A Dwek; Timothy M Block
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

3.  Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; F K Buadi; M Q Lacy; S Zeldenrust; S R Hayman; N Leung; T V Kourelis; W Gonsalves; R Chakraborty; S Russell; D Dingli; J A Lust; Y Lin; P Kapoor; R Go; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

4.  Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.

Authors:  Gustavo Ferrín; Manuel Rodríguez-Perálvarez; Patricia Aguilar-Melero; Isidora Ranchal; Camilo Llamoza; Clara I Linares; Sandra González-Rubio; Jordi Muntané; Javier Briceño; Pedro López-Cillero; José Luis Montero-Álvarez; Manuel de la Mata
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

5.  The injured liver induces hyperimmunoglobulinemia by failing to dispose of antigens and endotoxins in the portal system.

Authors:  Wen Ting Liu; Ying Ying Jing; Zhi Peng Han; Xiao Ning Li; Yan Liu; Fo Bao Lai; Rong Li; Qiu-Dong Zhao; Meng-Chao Wu; Li-Xin Wei
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

6.  Elevated Serum IgG Levels Positively Correlated with IL-27 May Indicate Poor Outcome in Patients with HBV-Related Acute-On-Chronic Liver Failure.

Authors:  Geng-Lin Zhang; Qi-Yi Zhao; Chan Xie; Liang Peng; Ting Zhang; Zhi-Liang Gao
Journal:  J Immunol Res       Date:  2019-05-06       Impact factor: 4.818

7.  Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection.

Authors:  Sha Lin; QinQin Sun; WeiLin Mao; Yu Chen
Journal:  Gastroenterol Res Pract       Date:  2016-03-30       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.